Disease · MONDO_0000491

limb ischemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. limb ischemia. Diseases, record MONDO_0000491. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000491

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: limb ischemia; Open Targets
Open Targets ID: MONDO_0000491; Open Targets
Other names: ischaemic disease of limb, ischemic disease of limb, limb ischaemic disease, limb ischemic disease; Open Targets
Disease Ontology: DOID:0050852; Disease Ontology
Highest stage of its drugs: Phase 3, for 10 of its 10 drugs, from ClinicalTrials.gov; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ASPIRIN	CHEMBL25	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BEMIPARIN	CHEMBL3707365	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DALTEPARIN SODIUM	CHEMBL1201460	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
ENOXAPARIN	CHEMBL1201685	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
ENOXAPARIN SODIUM	CHEMBL1201476	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NADROPARIN CALCIUM	CHEMBL2109204	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
TINZAPARIN	CHEMBL6068592	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
TINZAPARIN SODIUM	CHEMBL1201414	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	5	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
F10	Coagulation factor X	1	Coagulation factor X inhibitor	Phase 3	https://conductscience.org/library/genes/2159	Drugs and targets
P2RY12	P2Y purinoceptor 12	1	Purinergic receptor P2Y12 antagonist	Phase 3	https://conductscience.org/library/genes/64805	Drugs and targets
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02217501	Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities	Phase 3	159	2021-02-21	Peripheral Arterial Disease	ASPIRIN, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT04536272	Reduced Anticoagulation Targets in ECLS (RATE)	Phase 3	330		Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation, Bleeding, Thrombosis	HEPARIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: Number of Participants With First Occurrence of Bleeding	5 of 77	4 of 82	159	NCT02217501	Trial comparisons
DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: deaths from any cause	3 of 77	4 of 82	159	NCT02217501	Trial comparisons
DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death	13 of 77	16 of 82	159	NCT02217501	Trial comparisons
DAPT - Clinically Indicated Duration+12m vs DAPT - Clinically Indicated Duration: serious adverse events	27 of 77	37 of 82	159	NCT02217501	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42413523	DERIVED	1	PubMed
41527181	DERIVED	1	PubMed
40087802	DERIVED	1	PubMed
35578271	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000491

GET https://conductscience.org/api/diseases/v1/MONDO_0000491/drugs

API reference For AI assistants